Category: RenalSyndicate content

Renal

Simple, not sexy: Twitter docs weigh in on the future of renal denervation

May 28, 2014 by Arezu Sarvestani

Twitter-savvy physicians and researchers mull over the latest clinical results for Medtronic's renal denervation technology, calling for more common sense and less hype in treating hypertension.

Simple, not sexy: Twitter's docs weigh in on the future of renal denervation

EuroPCR 2014: Looking for hope for renal denervation

May 27, 2014 by Arezu Sarvestani

Doctors and researchers at this year's EuroPCR conference look for answers in Medtronic's landmark SYMPLICITY HTN-3 clinical trial, which failed to find that renal denervation works against hypertension.

EuroPCR 2014: Renal denervation remains in the limelight

Amid the hand-wringing and back-pedaling surrounding renal denervation, some physicians are still looking for ways to use the technology to treat patients with hypertension.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

May 22, 2014 by Arezu Sarvestani

St. Jude Medical says that its next-gen EnligHTN renal denervation system appears safe and effective in treating hypertension, but docs at this year's EuroPCR conference are calling for more robust clinical trials.

EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

EuroPCR 2014: Docs say renal denervation ads are putting 'marketing before science'

May 21, 2014 by Arezu Sarvestani

The marketing push for hypertension-treating renal denervation technology, clinical darling turned black sheep, has some doctors raising eyebrows at the EuroPCR conference in Paris this week.

EuroPCR 2014: Renal denervation looks alive in Europe

Attendees at this year's EuroPCR conference in Paris cast a wary eye on medical device makers' efforts to promote renal denervation in treatment of hypertension, taking to Twitter to note and sometimes chide companies for putting "marketing before science."

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Hypertension: Docs turn on renal denervation | MassDevice.com On Call

April 10, 2014 by Arezu Sarvestani

U.S. and E.U. cardiologists call for a hard check on global sales of renal denervation technology in the wake of Medtronic's disappointing SYMPLICITY HTN-3 study.

MassDevice.com On Call

MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.

ACC 2014: Conflicts in renal denervation, competition in valves

April 3, 2014 by Arezu Sarvestani

More results from Medtronic's hypertension studies continue to muddle the outlook for renal denervation as medtech titans vie for prime listing for their transcatheter valves.

fired/hired

The American College of Cardiology's annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic's (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ACC 2014: Medtronic details Symplicity renal denervation data

March 29, 2014 by Ingrid Mezo

Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said today at the American College of Cardiology's annual conference.

YYmeta

Medtronic (NYSE:MDT) revealed the details today of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp